Member Info for ForFXSake

Looks like they've started again

"Thanks Ria, whats you're exit strategy? 0.3 or 0.35?"

LOL! More like 0.245p for these 2%ers

Multibagger?

Ramptasticulicious!

Indeed

Even worse if you bought the shares

Soup, the Oxilio is worthless to Nuformix.

Weren't we all under the impression before the deal that they were only licensing it for oncology (i.e. treatment for cancer as opposed to the side-effects of treatment)? Then it transpired that we didn't retain any rights to development CINV ourselves.

Even if Oxilio did develop CINV, what is the most we could expect from them?

"With that in mind the key Q&A questions are around funding streams post October."

I would think investors should be more focussed on questioning BD activity to date.

People will remember that DG was engaged as a Business Development Consultant for a number of months prior to becoming executive director. A Proactive video was also released back in November touting Nuformix as 'showcasing' to a conference packed with potential partners:

https://www.proactiveinvestors.co.uk/companies/news/993498/nuformix-showcases-proprietary-tranilast-programme-to-potential-licensing-partners-993498.html

Surely some groundwork was done in that time (first contacts made etc...)

DG has said they have everything they need to push ahead with partnering. Investors should be more interested in learning how that is developing. That is the funding we should really be interested in now.

Seems little point in chasing further discounted, dilutive offerings to unamed 'institutionals' unless we can attract some interest from prospective partners.

It seems that there is a potential market for muscling in on SOC rather than just going it alone after all. Even big pharma are doing it.

New drug combo promises to hold back Ovarian cancer for FIVE YEARS  https://mol.im/a/12156223

"Current NHS treatment for those without the BRCA mutation typically involves surgery, chemotherapy and an immunotherapy drug called bevacizumab. But in this new study, which involved 1,100 patients, a third of participants received chemotherapy and bevacizumab followed by two other drugs: durvalumab and olaparib."

It's a shame NXP004 appears to have slipped onto the back burner. Still, if they can partner NXP002 with big pharma (as opposed to minnow associates via worthless licensing deals) then maybe focus will return to that somewhere down the road.

Funny how he's mysterious evaporated

Who said that?

Yep. Glad that's done.

I did say I was being flippant Whimax but it's always a pleasure to see you getting your knickers in a twist.

These videos are mainly put out on channels which reach no-one but an audience of traders. All that is likely to get us is a series of pump n dumps instead of touching base with partners who can make a real difference to the valuation....but maybe that's enough for you. At least you might get your 2% that way.

If the board are serious then there is much more work to be done. Satisfying the whims of short term traders will achieve nothing, I'm afraid.

I look forward to hearing more about the business development efforts that were undertaken in preparation for this good news that we recently received.

Whimax, the old faithful lapdog.

I know the score Soup, I've been waiting years just like you.

I'm just being flippant while enjoying a beer a barbecue in this 'heatwave' that we're currently enjoying.

I could do with a few free bags and not those paper ones either. I've stopped buying them since the supermarkets started to profiteer.

Also, I think DG needs to stop doing silly interviews and get out knocking on doors. Julian should be on the High Street with a placard too.

I think the issuing of the interrims was a necessary first step towards approaching potential partners.

Chairman's statement read well.

It's The painful that the assets are valued at more than twice the current market cap.

Time for some action on the BD front now.

Prior to becoming executive director, you'll remember Gooding was employed for a period of months as a Business Development Consultant.

I don't know what the focus of that work was, NXP004 or NXP002? I'm guessing it might have been a little early for NXP004. Hopefully it wasn't a complete waste of time and money and groundwork may have been done then which can help them at this point.

REDX are currently worth £107m at about 32p per share. A similar valuation for us would be 15p per share with the currently issued share volume.

It's interesting to note that their share price hit over £1.20 in the past 3 years. Not sure why it dropped so much in that time.

We have a very long way to go, price-wise. It's up to DG & Julian now. They have said there is nothing to stop BD moving forward. Let's see if they mean business or not.

To be expected after all that's happened Jiving.

I was a bit disappointed that DG didn't answer a straight "Yes" when asked if the news was transformational in the interview yesterday. However, he has basically said that they are good to go on the BD side and have what they need to get things moving.

I just hope Julian is as good for Nuformix BD as his past reputation would suggest. I also hope DG's relationship with a certain chat group (if that is the case) doesn't end up damaging prospects like the leaks of 2019 appeared to do.